Kefah Mokbel, Professor of Medicine (Honorary) at Cardiff University School of Medicine, shared on LinkedIn:
“ET use in ER-low BC treated with chemotherapy is declining. ET omission in ER-low BC treated with NAC with residual disease was associated with significantly worse overall survival.”
Title: Endocrine Therapy Omission in Estrogen Receptor-Low (1–10%) Early Stage Breast Cancer: An Updated Analysis of the NCDB Database.
Authors: Saskia Leonard, Tanya Hoskin, Grace Choong, Matthew Goetz, Judy Boughey.
You can also read: Thermal Ablation Shows Promise in Early-Stage Breast Cancer, but Evidence Remains Limited.
